Phase 1
Sunrise (Principal investigator: prof. dr. H.M.W. Verheul)
A phase I study of high-dose, intermittent sunitinib in patients with solid tumors.
VEGF vaccination (Principal investigator: prof. dr. H.M.W. Verheul / dr. J.J. van der Vliet)
A phase I open-label clinical trial, evaluating the therapeutic vaccine hVEGF26-104/RFASE in patients with advanced solid tumors.
NAPOLY (Principal Investigator: dr. C.W. Menke-van der Houven van Oordt)
A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec® docetaxel in Patients with Solid Tumours.
MACIST (Principal Investigator: dr. M. van Linde)
Phase Ib study of Metformin and Chloroquine in IDH1/2-mutated Solid Tumors (MACIST).
MedImmune MEDI0562 (Principal Investigator: dr. J. Voortman)
A Phase 1 Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination with Immune Therapeutic Agents in Adult Subjects with Advanced Solid Tumors.
D6014C00005 FE (Principal Investigator: dr. M. Labots)
A Randomised, Open-label, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of AZD1775 After Oral Dosing of a Capsule Formulation in Patients with Advanced Solid Tumours.
D6014C00007 CA (Principal Investigator: dr. M. Labots)
An Open-Label, Non-randomised, Multicentre study to allow continued access to AZD1775 for patients enrolled in AZD1775 Clinical Pharmacology studies protocols.
BAY 94-9343_18329 (Principal Investigator: prof. dr. H.M.W. Verheul / dr. M. Labots)
An open-label, Phase I study to assess the effect of itraconazole (CYP3A4 and P-gp inhibitor) on the pharmacokinetics of anetumab ravtansine and to assess the ECG effects, safety and immunogenicity of anetumab ravtansine given as a single agent and together with itraconazole in subjects with mesothelin-expressing advanced solid cancers.